Whole genome sequencing in early onset advanced heart failure
(2025) In Scientific Reports 15(1).- Abstract
The genetic contributions to early onset heart failure (HF) are incompletely understood. Genetic testing in advanced HF patients undergoing heart transplantation (HTx) may yield clinical benefits, but data is limited. We performed deep-coverage whole genome sequencing (WGS) in 102 Swedish HTx recipients. Gene lists were compiled through a systematic literature review. Variants were prioritized for pathogenicity and classified manually. We also compared polygenic HF risk scores to a population-based cohort. We found a pathogenic (LP/P) variant in 34 individuals (34%). Testing yield was highest in hypertrophic (63% LP/P carriers), dilated (40%) and arrhythmogenic right ventricular (33%) cardiomyopathy and lower in ischemic cardiomyopathy... (More)
The genetic contributions to early onset heart failure (HF) are incompletely understood. Genetic testing in advanced HF patients undergoing heart transplantation (HTx) may yield clinical benefits, but data is limited. We performed deep-coverage whole genome sequencing (WGS) in 102 Swedish HTx recipients. Gene lists were compiled through a systematic literature review. Variants were prioritized for pathogenicity and classified manually. We also compared polygenic HF risk scores to a population-based cohort. We found a pathogenic (LP/P) variant in 34 individuals (34%). Testing yield was highest in hypertrophic (63% LP/P carriers), dilated (40%) and arrhythmogenic right ventricular (33%) cardiomyopathy and lower in ischemic cardiomyopathy (10%). A family history was more common in LP/P variant carriers than in non-carriers but was present in less than half of carriers (44% vs 13%, P < 0.001), whereas age was similar. Polygenic risk scores were similar in HTx recipients and the population cohort. In conclusion, we observed a high prevalence of pathogenic cardiomyopathy gene variants in individuals with early-onset advanced HF, which could not accurately be ruled out by family history and age. In contrast, we did not observe higher polygenic risk scores in early onset advanced HF cases than in the general population.
(Less)
- author
- organization
-
- Cardiology
- EXODIAB: Excellence of Diabetes Research in Sweden
- Molecular Epidemiology and Cardiology (research group)
- Molecular Cardiology (research group)
- Cardiovascular Epigenetics (research group)
- Lund Hemodynamic Lab (research group)
- Division of Hematology and Clinical Immunology
- Cardiovascular Research - Hypertension (research group)
- EpiHealth: Epidemiology for Health
- MultiPark: Multidisciplinary research focused on Parkinson´s disease
- Molecular Vascular Physiology (research group)
- Thoracic Surgery
- Artificial Intelligence and Bioinformatics in Cardiothoracic Sciences (AIBCTS) (research group)
- Heart and Lung transplantation (research group)
- eSSENCE: The e-Science Collaboration
- Heparin bindning protein in cardiothoracic surgery (research group)
- Division of Clinical Genetics
- LUCC: Lund University Cancer Centre
- WCMM-Wallenberg Centre for Molecular Medicine
- Heart Failure and Mechanical Support (research group)
- publishing date
- 2025
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Cardiomyopathies, Genetics, Genomics, Heart failure, Heart transplantation
- in
- Scientific Reports
- volume
- 15
- issue
- 1
- article number
- 4306
- publisher
- Nature Publishing Group
- external identifiers
-
- scopus:85218201028
- pmid:39910139
- ISSN
- 2045-2322
- DOI
- 10.1038/s41598-025-88465-8
- language
- English
- LU publication?
- yes
- id
- df316b92-710d-41a0-bca5-962bab4d0d79
- date added to LUP
- 2025-06-09 10:24:58
- date last changed
- 2025-06-10 03:00:02
@article{df316b92-710d-41a0-bca5-962bab4d0d79, abstract = {{<p>The genetic contributions to early onset heart failure (HF) are incompletely understood. Genetic testing in advanced HF patients undergoing heart transplantation (HTx) may yield clinical benefits, but data is limited. We performed deep-coverage whole genome sequencing (WGS) in 102 Swedish HTx recipients. Gene lists were compiled through a systematic literature review. Variants were prioritized for pathogenicity and classified manually. We also compared polygenic HF risk scores to a population-based cohort. We found a pathogenic (LP/P) variant in 34 individuals (34%). Testing yield was highest in hypertrophic (63% LP/P carriers), dilated (40%) and arrhythmogenic right ventricular (33%) cardiomyopathy and lower in ischemic cardiomyopathy (10%). A family history was more common in LP/P variant carriers than in non-carriers but was present in less than half of carriers (44% vs 13%, P < 0.001), whereas age was similar. Polygenic risk scores were similar in HTx recipients and the population cohort. In conclusion, we observed a high prevalence of pathogenic cardiomyopathy gene variants in individuals with early-onset advanced HF, which could not accurately be ruled out by family history and age. In contrast, we did not observe higher polygenic risk scores in early onset advanced HF cases than in the general population.</p>}}, author = {{Linnér, Erik and Czuba, Tomasz and Gidlöf, Olof and Lundgren, Jakob and Bollano, Entela and Hellberg, Maria and Celik, Selvi and Pimpalwar, Neha and Rentzsch, Philipp and Martorella, Molly and Gummesson, Anders and Melander, Olle and Albinsson, Sebastian and Dellgren, Göran and Borén, Jan and Jeppsson, Anders and Lumbers, R. Thomas and Shah, Sonia and Nilsson, Johan and Natarajan, Pradeep and Lappalainen, Tuuli and Levin, Malin and Ehrencrona, Hans and Smith, J. Gustav}}, issn = {{2045-2322}}, keywords = {{Cardiomyopathies; Genetics; Genomics; Heart failure; Heart transplantation}}, language = {{eng}}, number = {{1}}, publisher = {{Nature Publishing Group}}, series = {{Scientific Reports}}, title = {{Whole genome sequencing in early onset advanced heart failure}}, url = {{http://dx.doi.org/10.1038/s41598-025-88465-8}}, doi = {{10.1038/s41598-025-88465-8}}, volume = {{15}}, year = {{2025}}, }